Galon Jérôme, Bruni Daniela
INSERM Laboratory of Integrative Cancer Immunology, Equipe Labellisée Ligue Contre le Cancer, Sorbonne Université, Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot, Centre de Recherche des Cordeliers, 75006, Paris, France.
Cancer Treat Res. 2020;180:197-211. doi: 10.1007/978-3-030-38862-1_7.
Colorectal cancer (CRC) represents a major public health challenges, with one of the highest incidences worldwide. The two affected anatomical sites in CRC, i.e. the colon and the rectum, share important underlying features, but often differ in terms of therapeutic management. Current guidelines for CRC define its clinical stratification according to classical, tumor cell-based and pathological parameters. Novel ground-breaking findings in the recent years revealed the prominent role of the immune system in shaping CRC development. This chapter provides a detailed overview of the main genomic and immune features driving (or hampering) CRC progression, with a focus on the main immune cells and factors shaping its evolution. Furthermore, we discuss how tumor-infiltrating immunity could be leveraged both for therapeutic and stratification purposes.
结直肠癌（CRC）是一项重大的公共卫生挑战，其发病率在全球范围内位居前列。CRC所累及的两个解剖部位，即结肠和直肠，具有一些重要的共同潜在特征，但在治疗管理方面往往存在差异。当前的CRC指南根据经典的、基于肿瘤细胞的和病理参数来定义其临床分层。近年来的一些开创性新发现揭示了免疫系统在CRC发展过程中的重要作用。本章详细概述了驱动（或阻碍）CRC进展的主要基因组和免疫特征，重点关注塑造其演变的主要免疫细胞和因素。此外，我们还讨论了如何利用肿瘤浸润免疫进行治疗和分层。
